MARKET

VYNT

VYNT

Vyant Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.280
+0.020
+0.89%
After Hours: 2.300 +0.02 +0.88% 16:20 09/21 EDT
OPEN
2.290
PREV CLOSE
2.260
HIGH
2.320
LOW
2.260
VOLUME
51.17K
TURNOVER
--
52 WEEK HIGH
17.50
52 WEEK LOW
2.108
MARKET CAP
66.09M
P/E (TTM)
-0.5572
1D
5D
1M
3M
1Y
5Y
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
VyantBio, Inc. ("Vyant Bio" or the "Company") (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system ("CNS") and oncology-related diseases. Today, Vyant Bio an...
GlobeNewswire · 09/09 12:00
New College Degrees Give Liberal-Arts Students More Business Courses
marketwatch.com · 09/03 12:27
20 Stocks Moving in Friday's Pre-Market Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
Benzinga · 09/03 11:01
Precipio Shares Up; American Oncology Network to Use HemeScreen in Lab
marketwatch.com · 08/26 15:14
Achilles Therapeutics Granted Patents for Cancer Detection
marketwatch.com · 08/25 12:31
Vyant Bio, Cyclica Team Up to Identify Compounds to Treat CDKL5 Deficiency Disorder
MT Newswires · 08/19 15:37
BRIEF-Vyant Bio And Cyclica Announce A Strategic Collaboration To Identify Compounds To Treat Cdkl5 Deficiency Disorder
reuters.com · 08/19 13:40
Vyant Bio, Cyclica Announce Strategic Collaboration To Identify Compounds To Treat CDKL5 Deficiency Disorder
Vyant Bio, Inc., (NASDAQ:VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug
Benzinga · 08/19 13:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VYNT. Analyze the recent business situations of Vyant Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VYNT stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 5.39M
% Owned: 18.59%
Shares Outstanding: 28.99M
TypeInstitutionsShares
Increased
8
992.37K
New
15
829.77K
Decreased
1
18.71K
Sold Out
4
201.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
John Fletcher
President/Chief Executive Officer/Director
John Roberts
Chief Financial Officer
Andrew LaFrence
Corporate Executive
Ralf Brandt
Senior Vice President
Barb Jones
Other/Director
Yung-Ping Yeh
Director
Marcus Boehm
Director
Paul Hansen
Director
Joanna Horobin
Independent Director
Geoffrey Harris
Independent Director
Howard McLeod
No Data
About VYNT
Vyant Bio, Inc., formerly Cancer Genetics, Inc., is a biotechnology drug discovery company. The Company is engaged in identifying molecule therapeutics and decision making through in silico, in vitro, and in vivo modalities. It offers AnalytiX platform, which analyzes functional data to identify the drug candidates, targets, and biomarkers via a rank order approach. Its microOrgan technology uses functional microtissues engineered from induced pluripotent stem cells (iPSC) to facilitate human-based drug discovery. It operates two subsidiaries, vivoPharm, Pty Ltd. (vivoPharm) and StemoniX, Inc. (StemoniX). Its subsidiary, vivoPharm, offers preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The StemoniX develops and manufactures human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development.

Webull offers kinds of Vyant Bio Inc stock information, including NASDAQ:VYNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNT stock methods without spending real money on the virtual paper trading platform.